Midostaurin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Midostaurin" in English language version.

refsWebsite

Global rank English rank

447^th place

338^th place

2^nd place

2^nd place

4^th place

4^th place

1,712^th place

1,063^rd place

68^th place

117^th place

6,094^th place

4,186^th place

399^th place

333^rd place

canada.ca

"Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.

confex.com

ash.confex.com

Stone RM, Mandrekar S, Sanford BL, Geyer S, Bloomfield CD, Dohner K, et al. (December 2015). The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). American Society of Hematology (ASH) 57th Annual Meeting. Orlando.{{cite conference}}: CS1 maint: overridden setting (link)

doi.org

Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, et al. (June 2002). "Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412". Cancer Cell. 1 (5): 433–43. doi:10.1016/S1535-6108(02)00069-7. PMID 12124173.{{cite journal}}: CS1 maint: overridden setting (link)
Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. (June 2016). "Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis". The New England Journal of Medicine. 374 (26): 2530–41. doi:10.1056/nejmoa1513098. PMID 27355533.{{cite journal}}: CS1 maint: overridden setting (link)

drugs.com

Drugs.com: rydapt overview.

europa.eu

ema.europa.eu

"Rydapt EPAR". European Medicines Agency. 18 September 2017. Retrieved 29 June 2024.

fda.gov

New Drug Therapy Approvals 2017 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2018. Retrieved 16 September 2020.
Office of the Commissioner. "Press Announcements - FDA approves new combination treatment for acute myeloid leukemia". www.fda.gov. Retrieved 4 May 2017.

nih.gov

pubmed.ncbi.nlm.nih.gov

Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, et al. (June 2002). "Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412". Cancer Cell. 1 (5): 433–43. doi:10.1016/S1535-6108(02)00069-7. PMID 12124173.{{cite journal}}: CS1 maint: overridden setting (link)
Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. (June 2016). "Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis". The New England Journal of Medicine. 374 (26): 2530–41. doi:10.1056/nejmoa1513098. PMID 27355533.{{cite journal}}: CS1 maint: overridden setting (link)